Acquired long QT syndrome presents with QT interval prolongation and carries a risk of arrhythmic events. Effective management requires a structured approach that addresses both reversible precipitating factors and, where appropriate, direct pharmacological intervention.
The protocol applies to patients with acquired QT interval prolongation, where identification and elimination of modifiable contributors is central to the care plan. Both drug-related and metabolic contributors to QT prolongation fall within scope.
Management encompasses targeted avoidance strategies — addressing specific drug exposures and electrolyte status — alongside pharmacotherapy for patients with documented QT interval prolongation. The choice and sequencing of interventions follows a structured evidence-based pathway.
The complete regimen — including agent selection, monitoring parameters, and decision criteria — is available in the full structured protocol.